SNN - Smith & Nephew SNATS - Stock & Dividends
Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US83175M2052
Knee Implants, Hip Implants, Wound Care, Surgical Instruments
Smith & Nephew plc is a global medical technology company that designs, manufactures, and markets a wide range of innovative medical devices and services. With a rich history dating back to 1856, the company has established itself as a leader in the healthcare industry, operating through three main segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
In the Orthopaedics segment, Smith & Nephew offers a comprehensive portfolio of products for joint reconstruction, including knee and hip implants, as well as trauma and extremities products for the treatment of severe fractures and deformity correction procedures. These products are designed to improve patient outcomes and enhance the quality of life for individuals with musculoskeletal conditions.
The Sports Medicine & ENT segment focuses on providing cutting-edge solutions for sports medicine joint repair, including instruments, technologies, and implants for minimally invasive surgery. This range of products enables surgeons to treat soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. Additionally, the company offers a suite of arthroscopic enabling technologies, such as fluid management equipment, high-definition cameras, and hand instruments, to facilitate visualization and treatment inside the joints.
In the Advanced Wound Management segment, Smith & Nephew provides a comprehensive range of products for the treatment and prevention of acute and chronic wounds. This includes advanced wound care products, such as leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds, as well as advanced wound bioactives, like biologics and other bioactive technologies for debridement and dermal repair/regeneration. The company also offers regenerative medicine products, including skin, bone graft, and articular cartilage substitutes, as well as advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems.
Smith & Nephew's products and services are designed to support healthcare providers in delivering high-quality patient care. With a strong commitment to innovation and customer satisfaction, the company continues to push the boundaries of medical technology, improving the lives of millions of people around the world. Headquartered in Watford, the United Kingdom, Smith & Nephew plc is a global leader in the medical technology industry.
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for SNN - Smith & Nephew SNATS - Stock & Dividends](https://www.valueray.com/images/drawdown_chart/SNN.NYSE_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for SNN - Smith & Nephew SNATS - Stock & Dividends](https://www.valueray.com/images/chart/SNN.NYSE_seasonality.png)
SNN Stock Overview
Market Cap in USD | 12,297m |
Sector | Healthcare |
Industry | Medical Devices |
GiC SubIndustry | Health Care Equipment |
TER | 0.00% |
IPO / Inception | 1999-11-16 |
SNN Stock Ratings
Growth 5y | -32.9 |
Fundamental | 55.1 |
Dividend | 36.1 |
Rel. Performance vs Sector | -0.23 |
Analysts | 4.50/5 |
Fair Price Momentum | 28.21 USD |
Fair Price DCF | 13.16 USD |
SNN Dividends
Dividend Yield 12m | 2.59% |
Yield on Cost 5y | 1.87% |
Dividends CAGR 5y | 0.60% |
Payout Consistency | 95.6% |
SNN Growth Ratios
Growth 12m | -2.72% |
Growth Correlation 12m | 7% |
Growth Correlation 3m | 50% |
CAGR 5y | -6.30% |
CAGR/Mean DD 5y | -0.21 |
Sharpe Ratio 12m | -0.36 |
Alpha vs SP500 12m | -24.88 |
Beta vs SP500 5y weekly | 1.09 |
ValueRay RSI | 92.19 |
Volatility GJR Garch 1y | 21.11% |
Price / SMA 50 | 10.17% |
Price / SMA 200 | 12.79% |
Current Volume | 633.5k |
Average Volume 20d | 1025k |
External Links for SNN Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of July 27, 2024, the stock is trading at USD 28.93 with a total of 633,521 shares traded.
Over the past week, the price has changed by +2.26%, over one month by +16.61%, over three months by +18.32% and over the past year by -1.75%.
According to ValueRays Forecast Model, SNN Smith & Nephew SNATS will be worth about 31.2 in July 2025. The stock is currently trading at 28.93. This means that the stock has a potential upside of +7.78%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 30.5 | 5.32 |
Analysts Target Price | 31.3 | 8.30 |
ValueRay Target Price | 31.2 | 7.78 |